Results unequivocally support early, aggressive, and sustained risk factor control in patients with complicated type 2 diabetes.
Scott Harris
Advertisement
Articles by Scott Harris
The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.
Advertisement
Latest Updated Articles
Intensive Program Extends Lifespan in T2D PatientsPublished: September 7th 2016 | Updated:
New Diabetes Drugs May Also Improve Kidney HealthPublished: August 25th 2016 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
EPIC-Norfolk Study Supports Universal Screening for Three Cardiovascular Biomarkers
2
Tezepelumab Achieves Dual Benefit in Severe Asthma, Improving Control with Reduced Steroid Dependence
3
Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care
4
Quiz: Recent Advances in Menopause and Midlife Women’s Health Research
5
